Mycobacterium abscessus is a rapidly growing, multidrug-resistant mycobacteria, commonly associated with pulmonary, skin, and soft tissue infections. We describe a rare case of M abscessus endovascular stent infection; only 3 cases of graft infections have previously been reported.
underwent aortoiliac bypass with saphenous vein grafting and stent removal. Cultures from the explanted stent and pseudoaneurysm grew M abscessus.
Mycobacterium abscessus isolates revealed susceptibilities to amikacin (minimum inhibitory concentration [MIC] , 16.0 µg/ mL) and linezolid (2.0 µg/mL), intermediate resistance to cefoxitin (32.0 µg/mL), and resistance to clarithromycin (>16.0 µg/mL), ciprofloxacin (>4 µg/mL), doxycycline (>16.0 µg/mL), moxifloxacin (4.0 µg/mL), imipenem (32 µg/mL), and trimethoprim/sulfamethoxazole (8/125 µg/mL); tigecycline MIC was 0.12 µg/mL.
He was treated with 15 mg/kg amikacin per day and 600 mg of linezolid twice daily for 6 months. His rash resolved (Image 1B). After stent removal, all blood cultures remained negative. Repeat transthoracic echocardiogram showed a normal mitral valve. Fifteen months after diagnosis, he remains clinically stable without any signs of recurrence.
Patient Consent and Confidentiality
The patient's written consent was obtained prior to the inclusion of photographs and radiographic images. These illustrations have been anonymized.
DISCUSSION
Disseminated M abscessus disease is rare [1] [2] [3] and carries a high mortality rate [4] [5] [6] [7] . Mycobacterium abscessus has been associated with various foreign body infections, including central venous catheters [4] , prosthetic heart valves [8] , and implanted pacemakers [9] . We highlight a unique case of disseminated disease from an infected endovascular stent. Becasuse M abscessus is ubiquitous in soil and water, our patient's infection was likely seeded by intravenous drug use involving tap water injection.
A review of reported endovascular graft-associated M abscessus cases [1] [2] [3] shows similar clinical characteristics (Table 1) , including a localizing rash or erythema ipsilateral to the infected vessel. Most cases presented 1 year or later after graft or stent placement. Bacteremia was evident within 7 to 10 days of presentation, which is typical of rapidly growing mycobacteria.
Positron emission tomography-CT proved useful in confirming graft or stent infection in instances in which CT or Doppler ultrasonography did not.
Widespread resistance to most antimicrobials is characteristic of M abscessus, making these infections challenging to treat [6, [10] [11] [12] . Amikacin appears to be the most active antimicrobial agent against M abscessus, with overall resistance rates of 7.7%, followed by clarithromycin (13.9%) and cefoxitin (15.1%) [10] . Intrinsic mechanisms of resistance include efflux pumps, antibiotic-inactivating enzymes, and genetic polymorphisms of antibiotic target genes [11] . Some M abscessus subspecies (particularly subspecies abscessus) have an active inducible macrolide resistance (erm) gene, leading to in vivo resistance to macrolides despite initial in vitro susceptibility [7, 12] , and have been associated with a higher mortality rate [7] . Thus, all clinically significant M abscessus isolates should undergo inducible macrolide resistance testing.
Optimal treatment for disseminated M abscessus infections is not well defined. Most experts recommend initial combination antimicrobial therapy with 2-3 active agents, preferably including amikacin [6, 10, 13, 14] . Some experts recommend transitioning initial combination therapy to oral active agents after 8-12 weeks, depending on susceptibilities, extent of disease, and antibiotic tolerability [14] . Treatment duration for disseminated disease is generally recommended for at least 6-12 months [8, 14] . Close monitoring for antibiotic-associated toxicities is required, presenting another challenge in treating these infections.
Surgical removal of foreign bodies, such as endovascular grafts, and debridement of infected foci are essential for cure [6, 9, 10] . Mycobacterium abscessus, more than any other rapidly growing mycobacteria, readily adheres to catheter surfaces via biofilm formation [5] . As our case and others have demonstrated (Table 1) , successful clearance of M abscessus bacteremia occurred after graft or stent removal and prolonged antibiotics [1] [2] [3] . 
CONCLUSIONS
Although it is a rare cause of endovascular infection, Mycobacterium abscessus can be a highly virulent mycobacteria with the potential to cause life-threatening, disseminated disease. This multidrug-resistant pathogen requires aggressive management, including prompt surgical intervention and prolonged combination antimicrobial therapy.
